ZILA--test for oral cancer? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZILA--test for oral cancer?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ivan Andrew who wrote (24)	6/13/1996 5:00:00 PM
From: Mark Fleming	of 61

A few comments: I believe the press release said ZILA had a 1/3 stake and is now purchasing the remaining 2/3. One justification for the CTM purchase was that it eliminates a legal dispute with CTM concerning the rights to OraTest. The press release went on to estimate the domestic market potential for OraTest at $0.5 Billion. ZILA also believes the cost of the acquisition is substantially less than the present value of the royalties they would have paid to CTM. (Is it reasonable to infer that any future earnings of CTM itself would be frosting on the cake, or would that have been factored into the calculations??) If you want to read tea leaves, the recent BDTC and CTM actions seem to indicate confidence of FDA approval and a desire not to share the jackpot with anybody.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next